EGFR and non-small cell lung carcinoma: A prospective multicenter single arm phase II clinical trial (NCT05338619) was conducted to evaluate the clinical efficacy and safety of Lazertinib as consolidation therapy for unresectable EGFR mutated positive NSCLC patients after synchronous radiotherapy and chemotherapy (34).